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Type II collagen-induced  arthritis  (CIA) in mice and rats is an inflammatory 
polyarthritis  that  displays  several  characteristics  similar  to  human  rheumatoid 
arthritis  (1,  2).  The  onset of CIA is associated with the development of both a 
cellular and humoral response to type II collagen (3) and is restricted in mice to 
animals  of the  H-2  q or  H-2  r  haplotype  (4).  The  humoral  response  to  type  II 
collagen  appears to  be an  essential  element in  the  development of the  disease 
although the role of cellular immunity is less clear. 
The L3T4 antigen, defined by a  rat anti-mouse monoclonal antibody GK1.5, 
is  limited  to  T  cells  responsible  for  class  II  major  histocompatibility  complex 
(MHC)-restricted  functions  and  is  analogous  to  the  OKT4/Leu-3  antigen  on 
human  T  cells  (5,  6).  Recent  reports  (7,  8)  have  indicated  that  treatment  of 
murine experimental autoimmune diseases with monoclonal anti-L3T4 antibody 
under either preventive or therapeutic  protocols dramatically decreases disease 
expression.  In this paper we demonstrate  the  prevention  of murine  CIA by in 
vivo treatment with monoclonai antibody to the L3T4 antigen. 
Materials and  Methods 
Animals.  DBA/1  male mice, 8-10 wk old, were obtained from The Jackson Labora- 
tory, Bar Harbor, ME. 
Type H Collagen.  Bovine articular cartilage was processed through four 24-h extrac- 
tions with  5  vol of 4  M  guanidine  HCI, 50  mM Tris, pH 7.0, at 4°C.  The slices  were 
washed twice for 2 h  in  1 M NaCI, 50 mM Tris, pH 7.5, once for 2 h  in distilled H20, 
and twice for 3 h with 0.5 M HAc, and then digested overnight with 10 vol of 200 ttg/ml 
pepsin in 0.5  M  HAc.  The digest was centrifuged for  1 h  at  10,000 g; solid NaCI was 
added to the supernatant to a concentration of 0.9 M and held overnight. After centrif- 
ugation, the pellet was resuspended in  5 vol of 1 M  NaCI, 50 mM Tris, pH 7.5.  The 
solution  was adjusted  to pH  8  by addition  of 3  N  NaOH and, after centrifugation as 
above,  the  supernatant  was  reprecipitated  by  the  addition  of solid  NaC!  to  a  final 
concentration of 4  M. After centrifugation, the pellet was suspended in 5 vol of 0.5  M 
HAc, dialyzed against 0.5  M HAc, and centrifugated at 27,000 g for 1 h. The purity of 
the type II collagen in the supernatant preparation was determined by sodium dodecyl 
sulphate gel electrophoresis,  which showed a  single band identical  to a  sample of pure 
bovine  type  II  collagen  (kindly  provided by  Dr.  Paul  Benya,  University  of Southern 
California School of Medicine). 
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Monoclonal  Antibodies.  Tbe hybridoma that produces monoclonal antibody GK1.5, a 
rat IgG2b monoclonal antibody recognizing L3T4, was passed in BALB/c mice irradiated 
with  500  rad.  The antibody was  isolated from the ascitic fluid by ammonium  sulfate 
precipitation followed by passage over a  PD-10 column and,  finally, by passage of the 
protein over a QAE Sephadex A50 column (Pharmacia Fine Chemicals, Piscataway, N  J) 
and  quantitation  by  ultraviolet absorption  at  280  nm.  The  following rat  anti-mouse 
monoclonal antibody-secreting hybridomas were developed by Dr. J. A.  Ledbetter (9) 
and obtained from the American Type Culture Collection, Rockville, MD: 30-H 12, anti- 
Thy- 1.2; 53-6.72, anti-Lyt-2; 53-7.313, anti-Lyt-  1. Antibody was obtained by growing the 
hybridoma cells in serum-free HB102 medium (DuPont Co., Wilmington, DE) for 24 h 
at 5 X 105/ml.  Supernatants were harvested, filtered, and used undiluted for cell pheno- 
type analysis. 
Induction of CIA.  DBA/1  mice were immunized with an intradermal injection of 100 
tag native type II collagen emulsified in an equal volume of complete Freund's adjuvant 
(CFA), followed on day 21 by an intraperitoneal injection of I00 tag native type II collagen 
in phosphate-buffered saline (PBS).  Control mice received injections of PBS.  After the 
second immunization, animals were inspected every other day for clinical signs of arthritis 
until day 53, and twice weekly thereafter. The onset of arthritis was defined by the first 
signs of erythema and swelling of one or more limbs.  In all instances it was subsequently 
confirmed by histologic examination. 
Anti-Type H Collagen ELISA.  Immulon II plates (Dynatech Laboratories, Alexandria, 
VA) were incubated for 4 h at 4°C with type II collagen in PBS, pH 7.4, at  10 #g/ml, 
100 tal/well.  The plates were washed with PBS, incubated for 2 h with PBS-I% bovine 
serum albumin  (BSA),  and washed repeatedly with  PBS-Tween. Antisera were serially 
diluted in 1% BSA-PBS-Tween and dispensed at 100 tal/well. After overnight incubation 
at 4°C, the plates were washed and goat anti-mouse IgG-alkaline phosphatase conjugate 
(Tago, Inc., Burlingame, CA) was added for 2 h. After addition ofp-nitrophenyl disodium 
(Sigma Chemical Co., St. Louis, MO), the reaction was stopped by addition of 50 tal 1 N 
NaOH to each well and the plates were read witb an automatic enzyme-linked immuno- 
sorbent assay  (ELISA) plate reader (Bio-Tek Instruments, Inc., Burlington, VT) at 405 
nm. Titers were based on comparison to an anti-type II collagen antibody standard that 
was included with each assay. 
Fluorescence Analysis of Lymphocyte Subpopulations.  Single-cell suspensions from spleens 
and lymph nodes were washed and suspended at 5 x  106/ml in 1% BSA-PBS-0.1% NAN3. 
50 ul of cell suspension and 50/~1 of monoclonal antisera were incubated for 30 min at 
4 o  C, washed once, and the cells resuspended in 50 tal of  fluorescein-conjugated  monoclonal 
mouse anti-rat kappa chain antibody (Becton, Dickinson & Co., Mountain View, CA) for 
30 min at 4°C. Control tubes were exposed only to the second antibody. After a final 
wash  the labeled cells were enumerated using a cytofluorograph flow cytometer (model 
2150; Ortho Diagnostic Systems, Raritan, N  J). 
Results 
In vivo effects of anti-L3T4  administration  on  T  cell subsets.  DBA/1  mice were 
given injections of 100 #g anti-L3T4 on day -  1 and + 1, followed by fluorescence- 
activated cell sorter (FACS) analysis of lymph node cells on days 3,  7,  14, and 
30. The results shown in Table I indicate that such treatments resulted in a 90% 
depletion of L3T4  + cells by day 3 associated with a decreased percentage of total 
T  cells.  The  remaining  T  cells  were predominantly of the  Lyt-2  + phenotype. 
After depletion, there was a  gradual  replenishment of the  L3T4  ÷ population, 
which returned to normal by day 30.  Similar results were observed with spleen 
cell populations (data not shown). 
Effects  of Anti-L3T4  on CIA.  Two protocols were designed to determine the 
effects of anti-L3T4 on type II collagen arthritis induction (Table II). In the first 
protocol, DBA/1  mice were treated with  100 ug of anti-L3T4  1 d  before and  1 
d after immunization with type II collagen, and once every 2 wk thereafter until RANGES  ET  AL.  BRIEF  DEFINITIVE  REPORT  1107 
TABLE  I 
Changes in T Cell Subset Distribution  after In Vivo 
GKI.5 
Administration  of 
Day after 
GK1.5 
Percent positive cells staining with: 
Thy- 1  Lyt- 1  Lyt-2  L3T4 
Untreated  68.7  79.4  19.6  51.9 
GK 1.5 Treated  3  5 I. l  53.3  45.7  6.9 
8  58.6  63.0  41.5  10.4 
14  59.0  65.3  33.6  16.1 
30  69.0  71.2  23.4  45.3 
DBA/I mice were given intraperitoneal injections of 100 #g GK1.5 on days -1  and 
+1. On days 3, 8,  14, and 30, axial and inguinal lymph node cells were removed and 
processed for FACS analysis. Each time point represents the average of three mice. 
Standard errors in each case were <5%. 
TABLE  II 
Incidence and Mean Day of Onset of CIA 
Exp. 
Group A  Group B  Group C 
CIA inci-  Mean day of  CIA incidence  Mean day of  CIA incidence  Mean day of 
dence  onset (±SD)  onset (±SD)  onset (±SD) 
1  9/10  44 -  6  2/10  80 _  5  5/10  45 ±  5 
2  5/10  34 ±  7  1/15  45  5/12  38 ± 8 
Totals  14/20  3/25 (P <  0.005)  10/22 (P >  0.19) 
CIA incidence is calculated as the number of mice displaying arthritis per number of mice in group. Group A, is 
control mice immunized with type 1I collagen and treated with PBS. Group B was immunized with type 11 collagen; 
injections of 100 #g GK1.5 on days -1, +1,  14, 28, 45. Group C was immunized with type 11 collagen; injections 
of 100 ug GK1.5 on days 28, 45 (Exp.  1) or on days 23 and every other day to day 50 (Exp. 2). P values, =  chi 
values comparing groups B and C with group A. 
day  45  (Table  II,  group  B).  In  the  second  protocol anti-L3T4  treatment  was 
delayed until a vigorous immune response to collagen was in progress, but before 
the clinical appearance of arthritis (Table II, Exp.  1, group C). 
The onset of arthritis in the control group (A) began at day 31 and by day 53 
reached  a  cumulative incidence  of 90%  (Table  II, Exp.  1).  The group of mice 
(B) receiving anti-L3T4  before immunization displayed no arthritis by day 53, 
but 2  of  10  mice  developed  arthritis  by  day  85,  some  40  d  after  cessation  of 
treatment.  By day  140, none of the remaining animals from this group showed 
any signs of arthritis. The third group (C), which did not receive anti-L3T4 until 
28 d  after immunization,  showed an arthritis incidence  of 50%  by day 54 with 
no further changes after that time. The results from group C were not statistically 
different from the control group (Table II). 
Anti-L3T4  treatments were successful in preventing CIA when administered 
before immunization with type II collagen but, if treatments were delayed 28 d, 
the effect was equivocal. To determine if delayed but more intensive treatment 
with anti-L3T4 would have an effect on CIA, immunized mice were treated with 
anti-L3T4 beginning on day 23 and every other day thereafter for the remainder 
of the experiment (Table II, Exp. 2, group C). No difference in arthritis incidence 
or day of onset was seen between this group and the control group. Therefore, 
anti-L3T4 was effective in preventing CIA when given before immunization but 
was  ineffective  once  a  vigorous  immune  response  to  type  II  collagen  was  in 
progress. 
Histologic evaluation  of arthritic and  nonarthritic  limbs.  T6 determine if some 1108  RANGES  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE Ill 
Summary of Anti-Type II Collagen Titers 
IgG titer ± SE 
Day 14  Day 28  Day 45  Day 70 
Group A control  767 -+ 104  853 ±  74  1,585 -+ 333  2,101 --. 755 
Group B (GK1.5 days -1,  0  264±73  412+  104  381_+  172 
+1, 14, 28, 45) 
Group C (GKI.5 days 28,  759 -  70  769 _+ 117  863 --. 238  1,748 ± 605 
45) 
IgG anticollagen antibody titers from control and GK1.5-treated mice (see Table II, Exp.  1). Sera was collected at 
days 14, 28, 45, and 70 after immunization with native type II collagen. 
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FIGURE  I.  Day 45  IgG anti-type II collagen titers from individual mice immunized on day 
0.  Data from individual animals from Table II, Exp.  1.  Group A, controls; group B, GK1.5 
day -1,  +1,  14,  28, 45; group C, GK1.5, day 28,  45.  (+) Mice displaying arthritis; (0) mice 
without arthritis. 
of the limbs from nonarthritic  mice had subclinical evidence of arthritis,  limbs 
were removed, fixed, sectioned, and stained  with hematoxylin-eosin.  Clinically 
involved and noninvolved limbs from arthritic mice were also examined histolog- 
ically, by an evaluator who did not know the clinical status. There was complete 
correlation  between  the  clinical  and  histologic  evaluation.  Thus,  limbs  from 
arthritic  or nonarthritic  mice that appeared free of clinical disease also showed 
no histologic evidence of arthritis. 
Effect of anti-L3T4 on anticollagen  antibody titer.  Serum samples were obtained 
on days 14, 30, 45, and 70 and the antibody titers from control mice and treated 
animals  are  shown in  Table  III.  Group  A  showed high  IgG antibody titers to 
type II collagen by day  14, which were enhanced by a  second injection of type 
I! collagen.  Titers from group B were not detectable on day  14 and remained 
significantly (P <  0.005) below the control titers through  day 70. Group C had 
antibody titers equal to the control group on days 14 and 28, at which time they 
received their  first injection of anti-L3T4.  On day 45  the average titer of this 
group was significantly lower than  the control (P <  0.1) but was equivalent by 
day 70. These data suggest that pretreatment with anti-L3T4 is associated with 
decreased anti-type II collagen IgG production in addition to decreased arthritis 
incidence.  Anti-L3T4  treatment  after  a  strong  IgG  response  to  collagen  was 
underway appeared  to delay the  antibody response  to the  second injection  of 
type II collagen, but did not affect the expression of the disease. 
A  comparison of antibody titer and arthritis  incidence for individual  animals 
revealed no strict correlation  in  groups  A  or C  (Fig.  1).  While all  the mice in RANGES  ET  AL.  BRIEF  DEFINITIVE  REPORT  1109 
these groups had high titers to type II collagen, those with the highest titers did 
not in all cases show signs of arthritis.  However, in group B, the two mice that 
eventually developed arthritis  had  the  highest  titers  of that  group.  A  possible 
explanation of these results is that a critical level of antibody must be reached to 
initiate arthritis development but that increases above this level do not necessarily 
influence  disease expression  or incidence.  These  findings  also underscore  the 
point that the presence of high antibody titer to type II collagen is not the only 
prerequisite for the development of arthritis. 
Discussion 
The  effects  of  the  in  vivo  administration  of  anti-L3T4  on  T  cell  subset 
distribution  and  CIA  expression  can  be summarized  as follows: (a)  treatment 
with anti-L3T4 resulted in a >90% deletion of the L3T4 ÷ population of T  cells 
in lymph nodes and spleen, which gradually returned to normal numbers by 30 
d  after  treatment;  (b) administration  of anti-L3T4  before immunization  with 
type II collagen resulted in significantly decreased incidence and delayed onset 
of CIA and was associated with lower IgG antibody titers to type II collagen; (c) 
treatment  with anti-L3T4  after  the antibody response  to type II collagen  was 
already  underway  but  before disease onset did not  significantly affect disease 
expression;  (d)  while  humoral  response  to  type  II  collagen  appears  to  be  a 
necessary prerequisite for CIA development, the presence and intensity of such 
a response is not predictive of disease expression. 
The mechanisms responsible for tissue damage in CIA are not fully resolved. 
Evidence for the involvement of both cellular and humoral immunity to type II 
collagen  has  been  reported  (10-12).  Our  finding  that  administration  of anti- 
L3T4  before  immunization  with  type  II  collagen  resulted  in  a  significantly 
decreased anticollagen  IgG response and lower incidence of arthritis supports a 
role for anticoilagen antibody in the induction of the disease, but does not answer 
the  question  of whether  cellular  mechanisms  may  be  involved  in  full  disease 
expression. 
The  precise  mechanism  by which  the  depletion  of L3T4 + cells reduces  the 
anticollagen  response is not known.  However, since the response to collagen is 
T  cell dependent (13), it is likely that the inhibition  is due to some quantitative 
reduction in helper ceil activity. It will be important to determine if the reduction 
in helper cell activity is due to simple depletion of helper cells, reversal of the 
helper to suppressor cell ratio, direct blocking effects upon helper cell function, 
or induction of suppressor cells. 
Administration  of anti-L3T4  antibody after the development of an antibody 
response  to type II  collagen  but before the  development of arthritis  failed to 
inhibit  the disease process. Although  this might  implicate the exclusive role of 
antibody to collagen in the development of the disease, it is also possible that the 
protocol adopted may not have been appropriate  for suppressing intrasynovial 
T  cell activity. 
The results of these experiments suggest a  critical role for L3T4 + T  cells in 
the pathogenesis of CIA with regard to helper activity in the development of the 
anticollagen response. Their role in the ongoing disease is less clear. The in vivo 
use of monoclonai antibody directed at distinct T  cell subsets offers a powerful 
tool  for  dissecting  this  process  and  may  lead  to  therapeutic  modalities  for 
autoimmune diseases in humans. 1110  RANGES  ET  AL.  BRIEF  DEFINITIVE REPORT 
Summary 
The effect of in vivo administration of monoclonal anti-L3T4 antibody on the 
development of murine collagen-induced arthritis (CIA) was assessed. Treatment 
with anti-L3T4 resulted in a  >90%  depletion of L3T4 + T  cells in lymph nodes 
and  spleen,  an  effect  that  appears  entirely  reversed  30  d  after  treatment. 
Administration of anti-L3T4 before immunization with type II collagen resulted 
in a  significant  decrease  in arthritis  incidence  and delayed onset of the disease 
while  treatment  begun  after  a  strong  anticollagen  IgG humoral  response  was 
underway was not effective in altering disease expression. These results suggest 
a prominent role for L3T4 + T  cells in the pathogenesis of CIA. 
Received  for publication  13 May 1985 and in revised form 18June 1985. 
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